Cargando…

Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’

Detalles Bibliográficos
Autores principales:	Yamada, Norikazu, Hirayama, Atsushi, Maeda, Hideaki, Sakagami, Satoru, Shikata, Hiroo, Prins, Martin H., Lensing, Anthonie W. A., Kato, Masaharu, Onuma, Junichi, Miyamoto, Yuki, Iekushi, Kazuma, Kajikawa, Mariko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877730/ https://www.ncbi.nlm.nih.gov/pubmed/27222638 http://dx.doi.org/10.1186/s12959-016-0085-1

Ejemplares similares

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
por: Yamada, Norikazu, et al.
Publicado: (2015)

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
por: Prins, Martin H, et al.
Publicado: (2013)

Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the EINSTEIN DVT and EINSTEIN PE Studies
por: Prandoni, Paolo, et al.
Publicado: (2015)

Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
por: Wang, Yuqi, et al.
Publicado: (2013)

Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the EINSTEIN PE Study
por: Fermann, Gregory J, et al.
Publicado: (2015)

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy
por: Wells, Philip S, et al.
Publicado: (2014)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
por: Lensing, Anthonie W. A., et al.
Publicado: (2018)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban‐treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding
por: Kline, Jeffrey A., et al.
Publicado: (2016)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
por: Prins, Martin H, et al.
Publicado: (2013)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study
por: Kubitza, Dagmar, et al.
Publicado: (2018)

Risk Factors for DVT/PE in Patients with Stroke and Intracranial Hemorrhage
por: Stecker, Mark, et al.
Publicado: (2014)

Risk Factors for DVT/PE in Patients with Stroke and Intracranial Hemorrhage
por: Stecker, Mark, et al.
Publicado: (2017)

Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
por: Palumbo, Joseph S., et al.
Publicado: (2022)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study
por: Ageno, Walter, et al.
Publicado: (2020)

Aortic thrombosis after DVT and PE in a young COVID-19 patient
por: Baltrūnas, Tomas, et al.
Publicado: (2021)

Rivaroxaban and the EINSTEIN clinical trial programme
por: Cohen, Alexander T., et al.
Publicado: (2019)

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)

A Case Report on VT from TV: DVT and PE from Prolonged Television Watching
por: Lucerna, Alan, et al.
Publicado: (2017)

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022)

Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Nakamura, Mashio, et al.
Publicado: (2023)

A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia
por: Derseh, Manaye Tamrie, et al.
Publicado: (2021)

Deep Vein Thrombosis (DVT) Prophylactic Team Activity to Support DVT Prevention Protocol for the Purpose of the Prophylaxis of Pulmonary Thromboembolism (PTE) and Operation
por: Tamura, Shozo, et al.
Publicado: (2021)

Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)
por: Fukuda, Ikuo, et al.
Publicado: (2021)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study
por: Paciullo, Francesco, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
por: Speed, Victoria, et al.
Publicado: (2021)

Diagnosis of DVT in the emergency department: adherence to guidelines
por: Skjærbæk, Christian
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_o1iho3h6bvupgf3auarq2s5bo2